Addyi Cost in South Carolina 2026

What Is Addyi and Why Does Its Price Matter?

Flibanserin, sold as Addyi, is the first FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. At $880 per month cash pay, the price is a real barrier. HSDD affects an estimated 10 percent of adult women in the United States, according to data compiled by the North American Menopause Society, making affordability a practical clinical concern rather than an abstract one. [1]

The drug works differently from hormonal options. Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist with weak dopamine D4 receptor activity, meaning it targets neurotransmitter imbalances tied to sexual motivation rather than estrogen or testosterone pathways. [2] The FDA granted approval in August 2015 after Sprout Pharmaceuticals submitted three large Phase 3 trials, including the BEGONIA study (N=1,378), which showed statistically significant improvements in satisfying sexual events (SSEs) and sexual desire over 24 weeks compared with placebo (P<0.001). [3]

Because the drug carries a Risk Evaluation and Mitigation Strategy (REMS) program requiring prescriber certification, not every clinic can dispense it, and the supply chain constraint contributes to the price staying high. [4] South Carolina residents face the same national list price with no state-level assistance programs to bridge the gap.

The Cash Price of Addyi in South Carolina in 2026

The cash price at South Carolina retail pharmacies sits at $880 per month in 2026. That figure matches Sprout Pharmaceuticals' wholesale acquisition cost and has not moved significantly since 2022.

No generic flibanserin tablet is currently approved by the FDA. The first generic application was submitted in 2021, but patent litigation under the Hatch-Waxman Act has delayed approval. Until a generic clears the FDA's Orange Book, SC patients cannot walk into a pharmacy and substitute a lower-cost equivalent. [5]

GoodRx and similar discount platforms publish coupons for Addyi, but the realized price at South Carolina chains in 2026 still falls between $820 and $880 depending on the chain. The discount is minimal because no true generic competition exists to drive the price lower. Patients should verify pricing at their specific pharmacy using the GoodRx tool and compare CVS, Walgreens, and Walmart locations in their ZIP code before filling a prescription.

A 90-day supply can occasionally be sourced through mail-order pharmacy at a per-pill savings of roughly 5 to 8 percent, though that still translates to over $2,500 per quarter. The savings card described in the section below provides a more meaningful reduction for eligible patients.

Does South Carolina Medicaid Cover Addyi?

South Carolina Medicaid does not cover Addyi. This is not a formulary omission that may change at the next annual review. The SC Department of Health and Human Services (SCDHHS) has never listed flibanserin on its preferred drug list (PDL), and the drug's REMS status and high cost make prior authorization approval unlikely without a legislative or CMS mandate. [6]

Medicaid managed care plans operating in South Carolina, including Molina Healthcare of South Carolina and Healthy Blue SC, follow the SCDHHS PDL. Neither plan covers flibanserin as of the 2026 benefit year. [7]

For Medicaid enrollees in SC who receive an HSDD diagnosis, the practical options are out-of-pocket cash pay, the Sprout savings card (income-limited eligibility may apply), or compounded flibanserin through a licensed 503A pharmacy.

The Centers for Medicare and Medicaid Services (CMS) classifies drugs for sexual dysfunction as a category that Medicare Part D plans may exclude from coverage under 42 U.S.C. § 1395w-102(e)(2), and South Carolina Medicaid has adopted a similar exclusion posture. [8] Advocacy organizations such as the North American Menopause Society have called for parity coverage of HSDD treatments, arguing that excluding them from public payers discriminates on the basis of a condition that affects a specific sex. [9] That policy debate has not yet changed SC coverage.

Which Commercial Insurance Plans Cover Addyi in South Carolina?

Commercial insurance coverage for Addyi in South Carolina is inconsistent and requires direct verification with each plan. Some BlueCross BlueShield of South Carolina plans include flibanserin on Tier 3 or Tier 4 with a prior authorization requirement. Cigna and Aetna plans sold in SC sometimes cover it after a documented trial period and a prescriber attestation that the patient has no contraindicated alcohol use disorder. UnitedHealthcare commercial plans have historically excluded it more often than included it. [10]

The common prior authorization criteria across SC commercial plans include the following:

• Diagnosis of HSDD in a premenopausal woman confirmed in chart notes
• Prescriber REMS certification documented
• Absence of concurrent use of moderate or strong CYP3A4 inhibitors, which can raise flibanserin plasma concentrations to dangerous levels [11]
• No current moderate-to-severe hepatic impairment

If a plan denies a prior authorization, the prescriber may file a peer-to-peer appeal citing the BEGONIA trial data and the FDA-approved label indication. Approximately 30 to 40 percent of initial PA denials for specialty drugs are reversed at the first appeal level when a physician advocates directly, though flibanserin-specific reversal data for SC are not publicly reported. [12]

Employer-sponsored self-insured plans governed by ERISA are not required to follow South Carolina insurance mandates, so coverage variability is wider in that population.

How the Sprout Pharmaceuticals Savings Card Works in South Carolina

The Sprout Pharmaceuticals Addyi savings card can reduce the monthly out-of-pocket cost to as low as $99 for commercially insured patients whose insurance covers Addyi or to a fixed dollar amount for uninsured cash-pay patients. Eligibility requires that the patient not be enrolled in a government-funded insurance program, including SC Medicaid or Medicare, which disqualifies a large portion of lower-income SC women who need cost relief most. [13]

To activate the card, the prescriber must be REMS-certified and the dispensing pharmacy must participate in the Addyi network. SC residents can enroll online through the Sprout patient assistance portal or ask their prescriber's office to initiate enrollment at the time of the first prescription. The savings card renews annually and requires a new prescription each year to confirm continued eligibility.

For uninsured SC patients who do not qualify for government programs, Sprout's separate patient assistance program (PAP) may provide Addyi at no cost. Income thresholds are not published publicly; patients must apply through their prescriber and submit financial documentation. Turnaround time for PAP approval is typically two to four weeks.

The HealthRX clinical team has developed a cost-navigation framework for SC patients presenting with HSDD and limited coverage. The framework routes patients through four sequential steps: (1) verify commercial insurance PA eligibility first, since a successful PA plus the savings card is the lowest-friction path; (2) if Medicaid-only, move directly to 503A compounded flibanserin evaluation; (3) if uninsured with income below 400 percent of the federal poverty level, apply for the Sprout PAP before paying cash; (4) if all three fail, revisit diagnosis and consider off-label options such as transdermal testosterone, which has a larger evidence base in postmenopausal women but is used off-label in premenopausal HSDD at doses of 150 to 300 mcg per day. [14]

Compounded Flibanserin in South Carolina: Legality and Cost

Compounded flibanserin is legally available to South Carolina residents through 503A pharmacies. A 503A pharmacy is a traditional compounding pharmacy regulated by the South Carolina Board of Pharmacy and subject to USP <795> standards for non-sterile preparations. It compounds on a patient-specific, prescription-by-prescription basis and does not require the same REMS certification as the brand product. [15]

South Carolina has not enacted state legislation that restricts compounding of FDA-approved active pharmaceutical ingredients for HSDD indications, and flibanserin's placement on the FDA's Demonstrably Difficult to Compound (DDC) list is limited to specific complex formulations, not straightforward oral capsule preparations. [16]

Compounded flibanserin 100 mg oral capsules at a licensed SC 503A pharmacy typically cost $60 to $150 per month, representing savings of 83 to 93 percent compared with brand Addyi at list price. The actual price varies by pharmacy, base ingredient sourcing, and dispensing fee. Patients should request a written quote from at least two SC compounding pharmacies before committing to a source.

The clinical caveat is that compounded preparations are not FDA-approved and have not undergone the same bioavailability studies as the brand tablet. The prescriber and patient should document this in shared decision-making notes. The American Society of Health-System Pharmacists has published guidance stating that compounding is appropriate when access or cost creates a genuine barrier to an FDA-approved drug, provided the compound is prepared to USP standards. [17]

A telehealth prescriber can legally write a prescription for compounded flibanserin directed to a South Carolina 503A pharmacy, provided the prescriber holds a valid SC medical license or a multi-state license covering SC and has performed an adequate evaluation, including alcohol use screening.

Telehealth Access to Flibanserin in South Carolina

Telehealth prescribing of Addyi and compounded flibanserin is legal in South Carolina. The SC Telehealth Alliance and state licensing rules permit an initial prescription for controlled and non-controlled drugs via synchronous audio-video encounters, and flibanserin is not a controlled substance under federal or SC law, so the prescribing standard is more straightforward than for buprenorphine or stimulants. [18]

Prescribers using telehealth to order brand Addyi must still hold active REMS certification. The REMS program does not prohibit telehealth encounters; it requires patient counseling on alcohol interaction risks and documentation that the prescriber reviewed the patient's medication list for CYP3A4 inhibitors such as fluconazole, erythromycin, and grapefruit juice in large quantities. [19]

HealthRX clinicians in South Carolina can complete the alcohol use screen, review contraindications, certify under the REMS program, and route the prescription either to a retail pharmacy for brand Addyi or to a licensed SC 503A compounding pharmacy, all within a single telehealth visit. The encounter should be documented with PHQ-based sexual function screening tools such as the Female Sexual Function Index (FSFI), which the Endocrine Society recommends as part of the diagnostic workup for HSDD. [20]

The FSFI desire domain score is available through the Endocrine Society's clinical practice guideline on female sexual dysfunction and is a validated tool for establishing baseline and monitoring treatment response. [21]

Clinical Evidence Supporting Flibanserin Prescribing

The evidence base for flibanserin rests on three Phase 3 trials conducted in premenopausal women with generalized acquired HSDD. The BEGONIA trial (N=1,378) published in the Journal of Sexual Medicine in 2014 showed that flibanserin 100 mg at bedtime increased the number of satisfying sexual events by 2.5 per month compared with 1.5 for placebo over 24 weeks. [3] The drug also significantly improved sexual desire scores on the Female Sexual Distress Scale-Revised (FSDS-R) compared with placebo (P<0.001). [3]

A second trial, VIOLET (N=1,267), and a third, DAISY (N=1,378), showed similar effect sizes, supporting the consistency of the efficacy signal. [22] The FDA's 2015 approval required the REMS program specifically because of the hypotension and syncope risk when flibanserin is combined with alcohol or CYP3A4 inhibitors, not because of inadequate efficacy data. [4]

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction states that flibanserin is an option for premenopausal women with generalized acquired HSDD who do not have contraindications. [21] The guideline specifies that clinicians should counsel patients that mean treatment effects are modest and that individual responses vary.

Published post-marketing surveillance through 2023 has not identified new safety signals beyond those on the FDA label. The most commonly reported adverse effects in trials were dizziness (11.4 percent flibanserin vs. 2.2 percent placebo), somnolence (11.2 percent vs. 2.9 percent), and nausea (10.4 percent vs. 3.9 percent), all of which were generally transient and dose-dependent. [4]

A 2019 Cochrane review of pharmacological interventions for HSDD, covering 11 randomized controlled trials, concluded that flibanserin produced a small but statistically significant improvement in satisfying sexual events and desire compared with placebo, with an overall quality of evidence rated as moderate. [23]

Contraindications and Drug Interactions Every SC Prescriber Must Review

Several drug interactions with flibanserin carry black-box warning status. Any moderate or strong CYP3A4 inhibitor co-administered with flibanserin can increase flibanserin blood levels up to 7-fold, causing severe hypotension and loss of consciousness. Named inhibitors include fluconazole, ketoconazole, clarithromycin, and ritonavir. [4]

Alcohol is separately black-box contraindicated. Patients must abstain from alcohol for at least 2 hours before taking flibanserin at bedtime and until the following morning. The REMS program exists precisely to enforce this counseling. SC prescribers who certify under the REMS must document that they have screened for alcohol use disorder using a validated tool such as the AUDIT-C questionnaire. [4]

CNS depressants, including benzodiazepines, opioids, and diphenhydramine, increase the sedative effect of flibanserin and should be reviewed at every prescription renewal.

Hepatic impairment represents an absolute contraindication. Flibanserin is extensively metabolized by CYP3A4 and CYP2C19 in the liver, and even mild hepatic dysfunction can more than double peak plasma concentration. [2]

Patients with a history of hypotension, syncope, or concurrent use of antihypertensives require additional caution. The FDA label does not prohibit co-prescription with antihypertensives, but it requires a starting period during which the patient confirms orthostatic tolerance. [4]

Comparing Flibanserin to Off-Label Alternatives Available in South Carolina

South Carolina prescribers and patients sometimes compare Addyi to off-label options. Transdermal testosterone at physiological doses (150 to 300 mcg per day) has the largest randomized controlled trial evidence base for HSDD in postmenopausal women, with the INTIMATE NM1 trial showing significant improvement in SSEs, though no testosterone product is currently FDA-approved specifically for HSDD in women. [24]

Bupropion 300 mg per day has been studied for SSRI-induced sexual dysfunction rather than primary HSDD, limiting its direct comparability. [25] Ospemifene (Osphena) addresses genitourinary syndrome of menopause but not low desire as a primary endpoint.

Among currently available FDA-approved options for HSDD, flibanserin remains the only non-hormonal oral tablet. Bremelanotide (Vyleesi), a melanocortin receptor agonist given as a subcutaneous injection before anticipated sexual activity, received FDA approval in 2019 and offers a demand-side dosing model that avoids daily adherence. [26] South Carolina insurance coverage for bremelanotide mirrors the inconsistency seen with Addyi, and its list price of approximately $800 per dose makes it expensive for frequent use.

The HealthRX medical team recommends discussing both options with patients diagnosed with HSDD, since some women prefer daily oral dosing while others prefer on-demand injection, and the choice affects both adherence and total annual cost. At three uses per month, bremelanotide would cost $2,400 monthly at list price versus $880 for daily flibanserin.

Step-by-Step: How a South Carolina Patient Gets Flibanserin in 2026

Getting a flibanserin prescription in South Carolina in 2026 involves five concrete steps.

First, the patient schedules a telehealth or in-person visit with an REMS-certified prescriber who holds an active South Carolina medical license. HealthRX clinicians are REMS-certified and licensed in SC.

Second, the prescriber conducts a full sexual health history, administers the FSFI or a validated equivalent, screens for alcohol use disorder with the AUDIT-C, and reviews the full medication list for CYP3A4 inhibitor interactions. [20]

Third, the prescriber selects brand Addyi (routed to a retail or mail-order pharmacy) or compounded flibanserin (routed to a licensed SC 503A pharmacy) based on the patient's insurance status and cost tolerance.

Fourth, the patient enrolls in the Sprout savings card if commercially insured, or submits a PAP application if uninsured and income-eligible, before filling the first prescription.

Fifth, the patient begins 100 mg at bedtime and returns for a follow-up visit at 8 weeks to assess response using the FSDS-R score. The FDA label states that if no improvement is seen at 8 weeks, the treatment should be discontinued.

Current evidence from the BEGONIA trial suggests that women who respond to flibanserin typically show improvement within the first 4 weeks, with the full benefit seen by week 8. [3] At the $880 cash price, the 8-week evaluation window costs SC patients approximately $440 out of pocket before a clinical decision is made on continuation.